Anemia in Chronic Kidney- Pipeline Insight, 2024

Anemia in Chronic Kidney- Pipeline Insight, 2024

DelveInsight’s, “Anemia in Chronic Kidney- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Anemia in Chronic Kidney pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Anemia in Chronic Kidney: Understanding

Anemia in Chronic Kidney: Overview

Anemia is a frequent complication of Chronic Kidney Disease. The major cause of anemia in patients with CKD is the decreased ability of kidneys to produce erythropoietin (EPO). Decreased erythrocyte counts leads to insufficient oxygen supply in organs and decreases mobility and activities in daily life, which ultimately leads to a poor quality of life. Anemia might begin in early stages of CKD and usually gets worse as CKD gets progress. Anemia in CKD is typically normocytic, normochromic, and hypoproliferative.

Symptoms

The symptoms of Anemia in Chronic Kidney Disease include:

• weakness
• fatigue, or feeling tired
• headaches
• problems with concentration
• paleness
• dizziness
• difficulty breathing or shortness of breath
• chest pain

Diagnosis

A diagnosis of Anemia in Chronic Kidney Disease is based upon a thorough clinical evaluation and a detailed patient history. The laboratory tests including RBC indices, Peripheral blood smear, Reticulocyte count Test are vital in the evaluation of anemia of chronic illness or chronic kidney disease. Diagnosis of anemia of renal disease is based on demonstration of renal insufficiency, normocytic anemia, and peripheral reticulocytopenia.

Treatment

Pateints with anemia with chronic kidney disease can be treated on an outpatient basis. Depending on the cause, treatments options include Iron Supplements, Erythropoiesis-stimulating agents (ESAs), Red Blood Cell Transfusions, and Vitamin B12 and Folic Acid Supplements.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Anemia in Chronic Kidney R&D. The therapies under development are focused on novel approaches to treat/improve Anemia in Chronic Kidney.

Anemia in Chronic Kidney Emerging Drugs Chapters

This segment of the Anemia in Chronic Kidney report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anemia in Chronic Kidney Emerging Drugs

BCD-066: Biocad

Erythropoietin-based therapy represents the primary treatment and prevention option for anemia in chronic kidney disease. BCD-066 is under Phase III equivalence studies to determine the efficacy and safety of BCD-066 and Aranesp® in treatment of anemia in end-stage chronic kidney disease patients on dialysis.

SSS17: Shenyang Sunshine Pharmaceutical

SSS17 is a selective small molecule inhibitor to hypoxia inducible factor proline hydroxylase. It is under Phase I development as an oral treatment for anemic patients with chronic kidney diseases. HIF-PH is a hypoxia inducible factor proline hydroxylase, a molecule which can improve the stability and half-life of hypoxia inducible factor α (HIFα), so as to motivate the secretion of erythropoietin, or EPO.

Further product details are provided in the report……..

Anemia in Chronic Kidney: Therapeutic Assessment

This segment of the report provides insights about the different Anemia in Chronic Kidney drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Anemia in Chronic Kidney

There are approx. 50+ key companies which are developing the therapies for Anemia in Chronic Kidney. The companies which have their Anemia in Chronic Kidney drug candidates in the most advanced stage, i.e. phase III include, Deerland Probiotics & Enzymes.

Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Anemia in Chronic Kidney pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anemia in Chronic Kidney: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anemia in Chronic Kidney therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anemia in Chronic Kidney drugs.

Anemia in Chronic Kidney Report Insights

• Anemia in Chronic Kidney Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Anemia in Chronic Kidney Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Anemia in Chronic Kidney drugs?
• How many Anemia in Chronic Kidney drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anemia in Chronic Kidney?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anemia in Chronic Kidney therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Anemia in Chronic Kidney and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jiangsu HengRui Medicine
• Shenyang Sunshine Pharmaceutical
• Biocad
• Xenetic Biosciences
• Chiasma
• Liminal BioSciences
• Acceleron Pharma
• Celgene Corporation

Key Products

• DDO-3055
• SSS17
• BCD-131
• BCD-066
• Erythropoietin polysialic
• CHIP 2
• PBI 1402
• Sotatercept